Gluconorm PG 1 Forte Tablet SR is a combination oral antihyperglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (1 mg), Metformin (1000 mg), and Pioglitazone (15 mg), each contributing distinct mechanisms to optimize blood glucose regulation. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, enhancing endogenous insulin release. Metformin, a biguanide, primarily reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, thereby decreasing glucose production and increasing glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. This sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma drug levels and improving patient compliance. Gluconorm PG 1 Forte is indicated for patients inadequately controlled on monotherapy or dual therapy and is to be used alongside diet and exercise modifications. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, liver function, and renal parameters is recommended to optimize therapy and minimize adverse effects.